Ribocure Pharmaceuticals AB

Distinguished Swedish Investors Back Leading Biotech Company in GoCo Health Innovation City to Advance siRNA Therapies

2 July 2025 09:10

Swedish investors Erik Selin and Jacob Torell join Ribocure as new shareholders with a total investment of $33 million, advancing Ribocure's multi-specific siRNA platform and CNS-delivery technology. This investment underscores the global interest in RNA-based therapeutics, enhancing Ribocure's potential for groundbreaking therapies in cardiovascular and neurodegenerative disorders.

Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug

7 April 2025 09:00

Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug

Kliniska studier kommer till vårdcentraler: Unikt samarbete bidrar till utvecklingen av morgondagens läkemedel

2 April 2025 15:45

Kliniska studier kommer till vårdcentraler: Unikt samarbete bidrar till utvecklingen av morgondagens läkemedel

Advancing siRNA Drug Discovery and Development with AI

14 March 2025 08:00

Advancing siRNA Drug Discovery and Development with AI

Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA

25 February 2025 09:42

Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA

First milestone successfully achieved in Ribo’s collaboration on liver diseases with Boehringer Ingelheim

9 January 2025 09:00

First milestone successfully achieved in Ribo’s collaboration on liver diseases with Boehringer Ingelheim

Ribo's siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia

29 October 2024 08:00

Ribo's siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia.

Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics

24 September 2024 13:00

Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics

Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5

20 September 2024 10:30

Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5

Ribo presented the first clinical data from our completed Ph1 study of the world´s first and most advanced hemostasis-sparing antithrombotic Factor XI (FXI) targeting siRNA asset, RBD4059, based on our RIBO-GalSTAR™ technology.

2 September 2024 07:54

Ribo presented the first clinical data from our completed Ph1 study of the world´s first and most advanced hemostasis-sparing antithrombotic Factor XI (FXI) targeting siRNA asset, RBD4059, based on our RIBO-GalSTAR™ technology.

Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the worlds first siRNA drug targeting Factor XI: RBD4059

29 May 2024 09:05

Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the worlds first siRNA drug targeting Factor XI: RBD4059

Ribo Receives Granted Patents for Phase 2 HBV siRNA Asset RBD1016 in United States and Europe

17 May 2024 15:24

Ribo Receives Granted Patents for Phase 2 HBV siRNA Asset RBD1016 in United States and Europe

Ribo & Ribocure successfully completed enrolment and dosing in the Phase 1 clinical trial, with world’s first siRNA drug targeting coagulation factor XI (FXI)

13 April 2024 09:28

Ribo & Ribocure successfully completed enrolment and dosing in the Phase 1 clinical trial, with world’s first siRNA drug targeting coagulation factor XI (FXI)

Innovating for a Healthier Tomorrow: Ribocure’s Role in Transforming Liver Disease Treatment with siRNA

28 March 2024 09:16

Ribocure Pharmaceuticals AB announces EMA authorisation to proceed with a Phase II clinical trial in Sweden. The trial will evaluate the efficacy and safety of its novel siRNA asset RBD1016, for the treatment of the rare disease of chronic hepatitis D infection.

Distinguished Swedish Investors Back Leading Biotech Company in GoCo Health Innovation City to Advance siRNA Therapies

Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug

Kliniska studier kommer till vårdcentraler: Unikt samarbete bidrar till utvecklingen av morgondagens läkemedel

Advancing siRNA Drug Discovery and Development with AI

Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA

First milestone successfully achieved in Ribo’s collaboration on liver diseases with Boehringer Ingelheim

Ribo's siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia

Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics

Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5

Ribo presented the first clinical data from our completed Ph1 study of the world´s first and most advanced hemostasis-sparing antithrombotic Factor XI (FXI) targeting siRNA asset, RBD4059, based on our RIBO-GalSTAR™ technology.

Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the worlds first siRNA drug targeting Factor XI: RBD4059

Ribo Receives Granted Patents for Phase 2 HBV siRNA Asset RBD1016 in United States and Europe

Ribo & Ribocure successfully completed enrolment and dosing in the Phase 1 clinical trial, with world’s first siRNA drug targeting coagulation factor XI (FXI)

Innovating for a Healthier Tomorrow: Ribocure’s Role in Transforming Liver Disease Treatment with siRNA

Ribocure supports RARE DISEASE DAY on February 29th

Ribo samarbetar med Boehringer Ingelheim för att utveckla nya behandlingar mot leversjukdomar

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Viktig milstolpe nådd när Ribocure Clinic tar in sina första patienter

Ribocure Clinic marks milestone with their first patients enrolled

Ribocure Pharmaceuticals invigde sina nya lokaler i GoCo Clinic huset den 30 juni 2023

Topics: Health, Health Care, Pharmaceuticals